Press Enter

Share with your friends and help them crack UPSC!

Or Share on

Answer

Correct Option is data from both the countries were not sufficient for any approval

Solution: Refer to the third paragraph of the passage which mentions, “Approving Covishield based on safety and immunogenicity data from the trial in India and efficacy data from the U.K. might be sufficient for emergency use. But it is imperative that Serum Institute collects efficacy data from the Indian trial before seeking full approval.” we can infer option (b). Hence correct choice is option (c).

Get access to all of our verified questions